3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Pancreatic Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Histologic Type
1
Leukemia, Myeloid, Acute
1
Carcinoma
1
BRAF V600E Mutation
1
Adenocarcinoma
1
Interventions
Cyclophosphamide
4
Gemcitabine
3
isatuximab
2
entrectinib
2
cobimetinib
2
capmatinib
2
atezolizumab
2
anlotinib
2
alectinib
2
Vemurafenib
2
Sunitinib
2
Rituximab
2
Lenalidomide
2
Dexamethasone
2
Cisplatin
2
trametinib
1
spartalizumab
1
pomalidomide
1
pertuzumab
1
penpulimab
1
pembrolizumab
1
olaparib
1
niraparib
1
lutetium Lu 177 dotatate
1
ibritumomab tiuxetan
1
fludarabine
1
dabrafenib
1
copper dotatate CU-64
1
Trastuzumab
1
Taxes
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasms by Histologic Type
×
Cobicistat
×
Clear all
NCT05494866
2025-03-25
IntenSify
German Cancer Research Center
Phase 1
Terminated
6 enrolled